China Resources Boya Bio-pharmaceutical Group Co., Ltd.

Shenzhen Stock Exchange 300294.SZ

China Resources Boya Bio-pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: 4.81%

China Resources Boya Bio-pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) is 4.81% for the year ending December 31, 2023, a -33.88% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
  • China Resources Boya Bio-pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 7.27%, a 15.64% change year over year.
  • China Resources Boya Bio-pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 6.29%, a -21.10% change year over year.
  • China Resources Boya Bio-pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 7.97%, a -36.28% change year over year.
  • China Resources Boya Bio-pharmaceutical Group Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 12.51%, a -11.18% change year over year.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
SV Wall Street
Shenzhen Stock Exchange: 300294.SZ

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

CEO Mr. Xiaoming Liang
IPO Date March 8, 2012
Location China
Headquarters No. 333, Huiquan Road
Employees 1,444
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Pet Food Plastics Vaccines
Description

China Resources Boya Bio-pharmaceutical Group Co., Ltd. engages in the blood products, diabetes medication, biochemical medication, and chemical medicine businesses in China. It engages in the research and development, production, and sales of blood products comprising human fibrinogen, intravenous human immunoglobulin, rabies immunoglobulin, human albumin, human immunoglobulin, freeze-dried intravenous human immunoglobulin, and hepatitis B human immunoglobulin; diabetes products, including metformin hydrochloride tablets/enteric-coated tablets, pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules; and compound osteotide, oxytocin, and heparin sodium injections for various fields, such as medicine, hepatitis, gynecology, and immunomodulation. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co., Ltd. China Resources Boya Bio-pharmaceutical Group Co., Ltd. was founded in 1993 and is based in Fuzhou, China.

StockViz Staff

February 2, 2025

Any question? Send us an email